Genetic Screening May Reduce Carbamazepine-Induced Cutaneous Adverse Reactions
Data may enable a more consistent approach to the safe administration of a commonly prescribed therapy.
Neurology Reviews. 2018 May;26(5):39
April 11, 2018|Epilepsy Resource Center
—Glenn S. Williams
Suggested Reading
Mushiroda T, Takahashi Y, Onuma T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol. 2018 Apr 2 [Epub ahead of print].
He Y, Seminario-Vidal S, McLeod HL. Avoidance of severe cutaneous adverse drug events as a first step in precision neurology. JAMA Neurol. Apr 2 [Epub ahead of print].
